Board Stats

Halozyme Therapeutics, Inc.

HALO / Message Board

BOARD

GROUPS

Written By On Topic Only -- All Messages

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

MSG #	SUBJECT	TYPE	AUTHOR	SENTIMENT	RECS	DATE POSTED
822	Re: Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints	GN	ladcad	Strong Buy	1	10/21/2023 8:35:53 AM

821	Re: Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints	GN	zake1		1	10/19/2023 8:44:47 AM

820	Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints	GN	Biotech2050		2	10/19/2023 7:25:15 AM

819	JPM on subcutaneous Opdivo	GN	Biotech2050		1	9/15/2023 8:30:04 AM

818	More from BMY Subcutaneous nivolumab	GN	Biotech2050		1	9/14/2023 11:25:56 AM

817	BMY's Important updates - subcutaneous nivolumab	GN	Biotech2050		0	9/14/2023 11:22:45 AM

816	Update: ENHANZE Drug Delivery Technology in Patients with Multiple Sclerosis	GN	Biotech2050		1	7/13/2023 5:48:40 AM

815	HALO's future	GN	ladcad	Strong Buy	1	6/21/2023 2:40:36 PM

814	Halozyme Announces argenx Receives FDA Approval for VYVGART� Hytrulo With ENHANZE	GN	Biotech2050		1	6/21/2023 12:09:03 AM

813	Muscular Dystrophy Association Celebrates FDA Approval of argenx's Vyvgart Hytrulo	GN	Biotech2050		0	6/21/2023 12:04:12 AM

Go to Msg #

BOARDS Sign In for Filters